Get started
Author

Tanya Granston

Observed names: Granston, Tanya, T Granston, T. Granston, Tanya S. Granston
OpenAlex ID: A5014292494
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
2018 · John Mascarenhas, Ronald Hoffman, et al. · JAMA Oncology · 400
PDF
Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium
2012 · Nathan D. Wong, Jennifer C. Nelson, et al. · JACC. Cardiovascular imaging · 163
PDF
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
2021 · Mary E. Rinella, Jean-Francois Dufour, et al. · Journal of Hepatology · 162
PDF
Current issues in the design and analysis of stepped wedge trials
2015 · James P. Hughes, Tanya S. Granston, et al. · Contemporary Clinical Trials · 131
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
2015 · Rami S. Komrokji, John F. Seymour, et al. · Blood · 120
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
2016 · Srdan Verstovsek, Olatoyosi Odenike, et al. · Journal of Hematology & Oncology · 92
PDF
The Relevance of Different Methods of Calculating the Ankle-Brachial Index: The Multi-Ethnic Study of Atherosclerosis
2009 · M. A. Allison, V. Aboyans, et al. · American Journal of Epidemiology · 40
Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl
2016 · John Mascarenhas, Ronald Hoffman, et al. · Blood · 37
Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial
2015 · Alessandro M. Vannucchi, Ruben A. Mesa, et al. · Blood · 8
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.
2016 · Ruben A. Mesa, Miklos Egyed, et al. · Journal of Clinical Oncology · 7
Earnings fraud: board control vs CEO control and corporate performance - 1992-2004
2010 · Don Warren, Mary Zey, et al. · Managerial and Decision Economics · 7
Addressing Lagged Effects and Interval Censoring in the Stepped Wedge Design of Cluster Randomized Clinical Trials
2014 · Tanya Granston · ResearchWorks at the University of Washington (University of Washington) · 4
PDF
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.
2016 · Ruben A. Mesa, Claire N. Harrison, et al. · Journal of Clinical Oncology · 1
Persist-1: a Phase Iii Study of Pacritinib (pac) Vs Best Available Therapy (bat) in Primary Myelofibrosis (pmf), Post-polycythemia Vera Mf (ppv-mf) or Post-essential Thrombocythemia Mf (pet-mf)
2015 · Claire Harrison, Andreı̈ Szöke, et al. · Haematologica · 1
Af.81 Noninvasive Assessments to Identify Patients With Advanced Fibrosis Due to Nash: Screened Population From the Regenerate Trial
2021 · S. Petta, J. Boursier, et al. · Digestive and Liver Disease
Pc.01.9 Evaluation of Obeticholic Acid Efficacy in Patients With Nash Who Were Monitored Using Noninvasive Tests: a Post Hoc Analysis of the Regenerate Trial
2021 · U. Vespasiani Gentilucci, N. Alkhouri, et al. · Digestive and Liver Disease
A217 Noninvasive Assessments to Identify Patients With Advanced Fibrosis Due to Nash: Screened Population From the Regenerate Trial
2021 · A J Montano-Loza, J Boursier, et al. · Journal of the Canadian Association of Gastroenterology
Obeticholic Acid Efficacy in Patients With NASH Monitored Using Noninvasive Tests: Post Hoc Analysis of REGENERATE Trial
2021 · N Alkhouri, A Sanyal, et al. · Zeitschrift für Gastroenterologie
Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)
2018 · Ruben A. Mesa, Francisco Cervantes, et al. · Blood
Additional file 1: Table S1. of Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
2016 · Verstovsek, Srdan, Odenike, Olatoyosi, et al. · Figshare
Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)
2015 · Ruben A. Mesa, Claire N. Harrison, et al. · Blood
Метаболический синдром, сахарный диабет: распространенность и прогрессирование кальцификации коронарных сосудов
2012 · ND Wong, Nelson Jc, et al. · CyberLeninK (CyberLeninka)
Works count: 25
Citation count: 1,173
H-index: 8
I10-index: 8
Year
Topic
Type